<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, the potential use of NPs as adjuvants in vaccines has been gaining interest. The inclusion of NPs in vaccine formulations has been reported to enhance antigen stability,
 <xref rid="irv12697-bib-0008" ref-type="ref">8</xref>, 
 <xref rid="irv12697-bib-0009" ref-type="ref">9</xref>, 
 <xref rid="irv12697-bib-0010" ref-type="ref">10</xref> promote targeted antigen delivery,
 <xref rid="irv12697-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="irv12697-bib-0012" ref-type="ref">12</xref> and assist slow release of antigens 
 <xref rid="irv12697-bib-0013" ref-type="ref">13</xref>, 
 <xref rid="irv12697-bib-0014" ref-type="ref">14</xref> to eliminate the need for booster shots.
 <xref rid="irv12697-bib-0015" ref-type="ref">15</xref>, 
 <xref rid="irv12697-bib-0016" ref-type="ref">16</xref> Different NPs have been evaluated for their ability to deliver antigens and increase immune responses against influenza antigens in vaccines. The current review focuses on the latest scientific advancement in the application of different NPs in influenza subunit vaccine development to enhance immunogenicity (Table 
 <xref rid="irv12697-tbl-0002" ref-type="table">2</xref>).
</p>
